Tech Company Financing Transactions

Annexon Biosciences Funding Round

New Enterprise Associates, Clarus and Correlation Ventures invested in a $44 million Series B capital raise for Annexon Biosciences. The financing round closed on 6/23/2016.

Transaction Overview

Company Name
Annexon Biosciences
Announced On
6/23/2016
Transaction Type
Venture Equity
Amount
$44,000,000
Round
Series B
Investors

New Enterprise Associates (Lead Investor) (Frank Torti)

Clarus (Emmett Cunningham)

Correlation Ventures

Novartis Venture Fund (Campbell Murray)

Satter Investment Management (Muneer Satter )

Proceeds Purpose
This significant investment in our robust and risk-balanced pipeline further validates Annexon's novel and elegant scientific approach. Moreover, the funding enables us to enhance and accelerate our biomarker-rich clinical development program in support of new and much-needed therapies for patients with serious neurodegenerative disorders.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
180 Kimball Way 2nd Floor 200
San Francisco, CA 94080
USA
Phone
(650) 822-5500
Website
www.annexonbio.com
Email Address
[email protected]
Overview
Annexon is a California-based healthcare company engaged in the R&D of novel disease-modifying drugs for neurodegenerative disorders.
Profile
Annexon Biosciences LinkedIn Company Profile
Social Media
Annexon Biosciences Company Twitter Account
Company News
Annexon Biosciences News
Facebook
Annexon Biosciences on Facebook
YouTube
Annexon Biosciences on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Douglas Love
  Douglas Love LinkedIn Profile  Douglas Love Twitter Account  Douglas Love News  Douglas Love on Facebook
Chief Financial Officer
Jennifer Lew
  Jennifer Lew LinkedIn Profile  Jennifer Lew Twitter Account  Jennifer Lew News  Jennifer Lew on Facebook
Chief Medical Officer
Sanjay Keswani
  Sanjay Keswani LinkedIn Profile  Sanjay Keswani Twitter Account  Sanjay Keswani News  Sanjay Keswani on Facebook
Chief Scientific Officer
Ted Yednock
  Ted Yednock LinkedIn Profile  Ted Yednock Twitter Account  Ted Yednock News  Ted Yednock on Facebook

 

 

Browse more venture capital transactions:

Prev: 6/23/2016: Lystable venture capital transaction
Next: 6/23/2016: PediaQ venture capital transaction

 

Share this article

 

Where The Data Comes From

We do our best to document all VC transactions involving tech companies. VC investment data records reported here are sourced from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.